Advertisement

Topics

Catalyst Biomedica Limited Company Profile

14:16 EST 20th November 2017 | BioPortfolio

Catalyst BioMedica is a company that enables and supports the translation of fundamental biomedical research into innovative products and technologies that will meet global healthcare needs. Catalyst is a business development subsidiary established by the Wellcome Trust to work with scientists and their host institutions. The Wellcome Trust is the world's largest medical research charity, with an annual expenditure of more than £600 million (US$900 million).

At Catalyst we aim to provide a complementary resource to University technology transfer professionals, to protect intellectual property, to administer the funding of selected applied research and to promote the delivery of benefits for healthcare. At the same time we want to ensure that the benefits of new technologies will be shared equitably among those who generate them and those who fund and facilitate their transfer to the commercial sector.

Location

183 Euston Road
London
NW1 2BE
United Kingdom

Contact

Phone: +44 (0) 207 611 8802
Fax: +44 (0) 207 611 8857
Email: catalyst@wellcome.ac.uk


News Articles [341 Associated News Articles listed on BioPortfolio]

Oxford BioMedica could pocket $100m on Novartis CAR-T cell success

Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.

Oxford BioMedica: Vector Value: An Interview with Nick Woolf, SVP Corporate Strategy

Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrate...

Oxford BioMedica inks $100 million supply agreement

Oxford BioMedica has signed an agreement for the commercial and clinical supply of lentiviral vectors…

Oxford BioMedica (OXB) - Kymriah approved - royalties to OXB assured

Edison Investment Research - Pharmaceutical & healthcare - Oxford BioMedica: Kymriah (tisagenlecleucel/CTL019), for which Oxford BioMedica (OXB) provides the key lentiviral vector component, has been ...

Oxford BioMedica secures commercial supply licence from UK MHRA

Oxford BioMedica has been granted a Manufacturer/Importer License (MIA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute lentiviral vector material...

Oxford BioMedica signs $100m CAR-T deal with Novartis

Oxford BioMedica has signed a deal worth up to $100m with Novartis to supply modified viruses used to generate its CAR-T therapies. The deal represents a major financial boost for the UK biotech fir...

Oxford BioMedica could get $100m following CAR-T approval

UK biotech Oxford BioMedica could earn more than $100 million from Novartis for providing a key component in the recently approved CAR-T cancer cell therapy. The FDA this week approved Novartis’ c...

Oxford BioMedica wins big contract for Novartis cell therapy

LONDON (Reuters) - Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with materia...

PubMed Articles [564 Associated PubMed Articles listed on BioPortfolio]

A solid iridium catalyst for diastereoselective hydrogenation.

An Ir(NHC) supported catalyst is used in the selective hydrogenation of terpinen-4-ol to cis p-menthan-4-ol. Its activity, selectivity and stability are compared to those of a homogeneous homologue [I...

Switch in Catalyst State: Single Bifunctional Bi-State Catalyst for Two Different Reactions.

Disclosed here is a molecular switch which responds to acid-base stimuli and serves as a bi-state catalyst for two different reactions. The two states of the switch serve as a highly active and poorly...

Overcoming the instability of nanoparticle based catalyst films in alkaline electrolysers by self-assembling and self-healing films.

Engineering stable electrodes using highly active catalyst nanopowders for electrochemical water splitting remains a notorious challenge. We report an innovative and general approach for attaining hig...

Microstructural observation of fuel cell catalyst inks by Cryo-SEM and Cryo-TEM.

In order to improve the electricity generation performance of fuel cell electric vehicles, it is necessary to optimize the microstructure of the catalyst layer of a polymer electrolyte fuel cell. The ...

The Experimental Measurement of Local and Bulk Oxygen Transport Resistances in the Catalyst Layer of Proton Exchange Membrane Fuel Cells.

Remarkable progress has been made in reducing the cathodic Pt loading of PEMFCs, however, a huge performance loss appears at high current densities, indicating the existence of a large oxygen transpor...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Chemotherapy regimens for pancreatic cancer can now stabilize a patient's cancer and/or place some patients in remission or partial remission. The challenge now is to find options for main...

Basic Knowledge of CPR Among Close Relatives of Heart Patients-check Status Quo and Attemp to Establish a Potential Plan to Implement This Knowledge

Cardiac arrest is a public health problem and is the leading cause of death in many parts of the world. Cardiac arrest can occur inside the hospital and outside it. In the United States a...

Companies [194 Associated Companies listed on BioPortfolio]

Catalyst Biomedica Limited

Catalyst BioMedica is a company that enables and supports the translation of fundamental biomedical research into innovative products and technologies that will meet global healthcare needs. Catalyst ...

Oxford BioMedica

Oxford BioMedica advanced gene therapy techniques.

Boston Biomedica Incorporated

Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases (ID) such as AIDS, Lyme Disease, and Viral He...

Catalyst Health and Technology Partners

Catalyst Health and Technology Partners (“Catalyst”), is a venture capital firm dedicated to helping promising early-stage health care, life science, and technology ventures grow.Catalyst is focus...

General Catalyst Partners

General Catalyst Partners is a growth equity and venture capital firm that invests in exceptional entrepreneurs who are building the technology-based companies that will lead inno...

More Information about "Catalyst Biomedica Limited" on BioPortfolio

We have published hundreds of Catalyst Biomedica Limited news stories on BioPortfolio along with dozens of Catalyst Biomedica Limited Clinical Trials and PubMed Articles about Catalyst Biomedica Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Catalyst Biomedica Limited Companies in our database. You can also find out about relevant Catalyst Biomedica Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...


Corporate Database Quicklinks



Searches Linking to this Company Record